Sinovac Biotech, Ltd
Sinovac Biotech Ltd. is a biopharmaceutical company focused on researching, manufacturing, and commercializing vaccines and related biological products for human infectious diseases. Its portfolio includes established vaccines and product candidates spanning influenza, hepatitis, varicella, polio, rabies, tetanus, pneumococcal disease, and newer vaccine platforms.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaLicensed and marketed vaccines used for prevention of infectious diseases.
Vaccines developed for major public health emergencies and outbreak response.
WHO-prequalified products suited for international procurement and public programs.
Combination vaccines, recombinant protein vaccines, mRNA and antibody candidates.
Asiakkaat
SINOVAC sells primarily to public health systems, vaccination programs, and healthcare distributors that procure vaccines for population immunization. It also serves international agencies and local partners that need WHO-prequalified or locally adapted vaccine supply.
Buy vaccines for national immunization programs and outbreak response.
Source WHO-prequalified vaccines for global health and aid programs.
Distribute and register vaccines in specific countries or regions.
Use selected vaccines in clinics and hospitals for patient immunization.
Collaborate on clinical development, technology transfer, and localized production.
Strategia
SINOVAC’s strategy centers on expanding its vaccine portfolio, progressing late-stage clinical programs, and adding newer technology platforms such as mRNA and antibody-based products. It also seeks to widen its global footprint through research partnerships, local manufacturing, and market access arrangements that support vaccine supply in multiple regions.
New products are needed to replenish the portfolio and extend growth beyond existing franchises.
Broader geographic reach reduces reliance on any single market and improves commercial optionality.
New platforms can improve future competitiveness and support responses to emerging infectious diseases.
Maantiede
2024SINOVAC is headquartered in China and operates as a global vaccine business with sales, R&D, and manufacturing tied to the Chinese market and overseas partnerships. Its products are designed for both domestic disease-prevention needs and international supply, including vaccines with WHO prequalification for broader global access.
Riskit
SINOVAC faces clinical, regulatory, and commercialization risk because vaccine candidates must progress through lengthy trials and market authorization processes before generating revenue. It is also exposed to demand concentration in public-sector procurement, competition from other vaccine developers, and execution risks tied to manufacturing quality, technology transfer, and global distribution.
- Regulatory approval delaysVaikutus: KorkeaTodennäköisyys: Korkea
Vaccines require country-by-country registration and authorization, which can slow commercialization.
Kohdistuu: International expansion and new product launches
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Vaccine candidates must complete trials and meet efficacy and safety standards before approval.
Kohdistuu: Pipeline products such as PCV13 and next-generation vaccines
- Manufacturing and quality controlVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biologics require stringent production consistency, cold-chain handling, and regulatory compliance.
Kohdistuu: Vaccine manufacturing and supply
- Customer concentration in public procurementVaikutus: KeskitasoTodennäköisyys: Korkea
A large share of vaccine demand is driven by governments and agencies that buy in batches and through tenders.
Kohdistuu: National immunization programs and public health buyers
- Competitive and technological changeVaikutus: KeskitasoTodennäköisyys: Kohtalainen
New vaccine platforms and competitors can shift demand toward newer products or lower-cost alternatives.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätSales can depend on shipment milestones and government procurement cycles.
Vaikutus: Quarterly comparability and revenue volatility
Prior acquisitions or product assets may need write-downs if prospects weaken.
Vaikutus: Operating income and asset base
Wealth management products and short-term investments can create mark-to-market or realized gains/losses.
Vaikutus: Other income and cash flow
Receivables and related-party balances require estimation of collectability.
Vaikutus: Net income and balance-sheet allowances
Long-term incentive plans and bonuses can create significant period-specific expenses and cash outflows.
Vaikutus: Operating expense and operating cash flow
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Dynavax Technologies Corp
Pharmaceutical Preparations
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
Valneva SE
VALN · Biological Products, (No Diagnostic Substances)
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases.
SIGA Technologies Inc
SIGA · Pharmaceutical Preparations
SIGA Technologies is a U.S.-based pharmaceutical company focused on developing and commercializing treatments for orthopoxvirus infections, centered on its…
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Päivitetty: 28.9.2026